Target's General Information
Target ID T67207
Target Name Lymphocyte IgE receptor (CD23)
Synonyms Low affinity immunoglobulin epsilon Fc receptor soluble form; Low affinity immunoglobulin epsilon Fc receptor; Immunoglobulin Ebinding factor; FcepsilonRII; FCER2; Ctype lectin domain family 4 member J; CD23; BLAST2
Target Type Clinical trial
Gene Name FCER2
Biochemical Class Immunoglobulin
UniProt ID FCER2_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Acute myelocytic leukemia
Example drug Lumiliximab Phase 2 [1], [2], [3]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.1
Z-score: -0.23
P-value: 9.88E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 ClinicalTrials.gov (NCT00391066) Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.